Is Pulse Pressure a Predictor of New-Onset Diabetes in High-Risk Hypertensive Patients?: A subanalysis of the Candesartan Antihypertensive Survival Evaluation in Japan (CASE-J) trial by Yasuno, Shinji et al.
Is Pulse Pressure a Predictor of New-Onset
Diabetes in High-Risk Hypertensive
Patients?
A subanalysis of the Candesartan Antihypertensive Survival Evaluation in
Japan (CASE-J) trial
SHINJI YASUNO, MD, PHD
1
KENJI UESHIMA, MD, PHD
1
KOJI OBA, MS
1
AKIRA FUJIMOTO, MS
1
MASAKAZU HIRATA, MD, PHD
2
TOSHIO OGIHARA, MD, PHD
3
TAKAO SARUTA, MD, PHD
4
KAZUWA NAKAO, MD, PHD
1,2
OBJECTIVE — Hypertensive patients have an increased risk of developing diabetes. Accu-
mulatingevidencesuggestsacloserelationbetweenmetabolicdisturbanceandincreasedarterial
stiffness. Here, we examined the association between pulse pressure and the risk of new-onset
diabetes in high-risk Japanese hypertensive patients.
RESEARCH DESIGN AND METHODS — The Candesartan Antihypertensive Survival
Evaluation in Japan (CASE-J) trial examined the effects of candesartan and amlodipine on the
incidence of cardiovascular events in 4,728 high-risk Japanese hypertensive patients. In the
present study, we analyzed the relationship between pulse pressure at baseline and new-onset
diabetes in 2,685 patients without diabetes at baseline (male 1,471; mean age 63.7 years; mean
BMI 24.8 kg/m
2) as a subanalysis of the CASE-J trial.
RESULTS — During 3.3  0.8 years of follow-up, 97 patients (3.6%) developed diabetes. In
multiple Cox regression analysis, pulse pressure was an independent predictor for new-onset
diabetes (hazard ratio [HR] per 1 SD increase 1.44 [95% CI 1.15–1.79]) as were male sex, BMI,
and additional use of diuretics, whereas age and heart rate were not. Plots of HRs for new-onset
diabetesconsideringbothsystolicanddiastolicbloodpressure(DBP)revealedthatahigherpulse
pressure with a lower DBP, indicating that the increased pulse pressure was largely due to
increased arterial stiffness, was strongly associated with the risk of new-onset diabetes.
CONCLUSIONS — Pulse pressure is an independent predictor of new-onset diabetes in
high-risk Japanese hypertensive patients. Increased arterial stiffness may be involved in the
development of diabetes.
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D
eaths from cardiovascular disease
(CVD), which, as the leading cause
of death, accounts for one-third of
alldeathsglobally,areforecasttoincrease
from 17.1 million in 2004 to 23.4 million
in 2030 (1). Hypertension is an estab-
lished risk factor for cardiovascular mor-
tality and morbidity through its effect on
several target organs, including the brain,
heart, and kidneys (2). Diabetes is also
strongly associated with an increased risk
of cardiovascular events (3). Because hy-
pertensive patients have an increased risk
of developing diabetes (new-onset diabe-
tes),thetwoconditionsfrequentlycluster
together and synergistically increase the
propensity to CVD (4). Further, a recent
study has shown that new-onset diabetes
negatively affects the incidence of cardio-
vascular morbidity and mortality to the
same degree as known diabetes (5). Pre-
ventionofnew-onsetdiabetesistherefore
an important issue in the management of
hypertension,andseveralstudieswiththe
aim of determining predictors of new-
onset diabetes have been reported (6–8).
Oneindependentpredictorofcardio-
vascular morbidity and mortality in hy-
pertensive patients is pulse pressure (9).
Although pulse pressure derives from the
interactionofcardiacejection(strokevol-
ume) and the properties of arterial circu-
lation (arterial stiffness and wave
reﬂection), elevated pulse pressure is
thought to be largely associated with in-
creased arterial stiffness due to aging, ar-
teriosclerosis, or both (9,10), and several
recent studies have reported an associa-
tionamongincreasedarterialstiffnessand
impaired glucose metabolism, metabolic
syndrome, and insulin resistance (11–
13). These ﬁndings suggest a possible as-
sociation between increased pulse
pressure and new-onset diabetes, but this
association has not been examined in hy-
pertensive patients.
The CASE-J trial was designed to
compare the long-term effects of the an-
giotensin II receptor blocker (ARB) can-
desartancilexetilandthecalciumchannel
blocker(CCB)amlodipinebesylateonthe
incidence of cardiovascular events in
4,728 high-risk Japanese hypertensive
patients (14). Results showed that both
treatment-based regimens lowered sys-
tolic (SBP) and diastolic blood pressure
(DBP) levels to 140/80 mmHg, and no
statisticallysigniﬁcantdifferencewasseen
in the incidence of primary cardiovascu-
lar events. However, candesartan-based
regimens signiﬁcantly suppressed the in-
cidence of new-onset diabetes compared
with amlodipine-based regimens (15).
Here, we report a subanalysis of the
CASE-J trial with the aim of determining
whether pulse pressure is associated with
the risk of new-onset diabetes indepen-
dent of the effects of antihypertensive
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for diabetes.
RESEARCH DESIGN AND
METHODS— The CASE-J trial was a
prospective, multicenter, randomized,
open-label, active-controlled, two-arm
parallel-group comparison with re-
sponse-dependent dose titration and
blinded assessment of end points con-
ductedinhigh-riskJapanesehypertensive
patients. The trial protocol was approved
bytheEthicsCommitteeofKyotoUniver-
sity Graduate School of Medicine in ac-
cordance with the principles of the
Declaration of Helsinki. Details of the
study and the main results have been re-
ported previously (14,15). In brief, 4,728
high-risk Japanese hypertensive patients
aged 20–84 years were randomly as-
signed to either candesartan- or amlodip-
ine-based regimens. Blood pressure was
measuredataclinicwiththepatientinthe
sitting position. The average of two con-
secutive measurements of blood pressure
onseparatevisitswasused.High-riskwas
deﬁned as the presence of any one or
moreofthefollowing:1)severehyperten-
sion (SBP/DBP 180/110 mmHg); 2)
type 2 diabetes (fasting blood glucose
126 mg/dl, casual blood glucose 200
mg/dl,A1C6.5%,2-hbloodglucoseon
a 75-g oral glucose tolerance test 200
mg/dl, or current treatment with a hypo-
glycemic agent at baseline); 3) a history of
stroke or transient ischemic attack  6
months before screening; 4) left ventricu-
lar hypertrophy (LVH), angina pectoris,
or a history of myocardial infarction 6
months before screening; 5) proteinuria
or renal dysfunction (serum creatinine
1.3 mg/dl); or 6) arteriosclerotic pe-
ripheralarteryobstruction.Exclusioncri-
teria have been reported elsewhere
(14,15).
Enrolled patients were randomly as-
signed to receive candesartan by oral ad-
ministration at 4–12 mg/day or
amlodipine by oral administration at
2.5–10 mg/day. Patients already under
treatment with diuretics, -blockers, and
-blockers at enrollment were allowed to
continue taking these drugs, but the new
addition of other ARBs and CCBs or any
ACE inhibitors was prohibited.
Outcome measurement
Of the 4,703 high-risk hypertensive pa-
tients analyzed in the CASE-J trial, 2,018
who had diabetes at baseline were ex-
cluded, leaving 2,685 patients for inclu-
sion in the present study. New-onset
diabeteswasprespeciﬁedastheendpoint
on 17 September 2005, which was after
the beginning but before the completion
of the CASE-J trial (15). To detect the oc-
currence of new-onset diabetes, individ-
ual case report forms and adverse-event
databases were monitored. A case of new-
onset diabetes was deﬁned as a patient
reported as having developed diabetes on
the adverse event form or a patient who
had newly started antidiabetic agent ther-
apy in the case report form. Written in-
formed consent was obtained from each
participating patient before allocation.
Statistical analysis
DataareexpressedasmeansSDorpro-
portions. Continuous variables were
compared using Student’s t test. Fre-
quency analysis was performed with the

2 test. Pulse pressure was calculated as
the difference between SBP and DBP.
MultipleCoxregressionanalysiswasused
to examine the association between each
blood pressure index (SBP, DBP, and
pulse pressure) at baseline and the risk of
new-onset diabetes with adjustment for
baseline characteristics (prior antihyper-
tensive treatment, allocated drug, age,
sex,BMI,heartrate,historyofcerebrovas-
cular events, LVH, history of ischemic
heart disease, renal dysfunction, periph-
eralvasculardisease,hyperlipidemia,and
smoking) as standard covariates and ad-
ditional drugs (diuretics, -blockers, and
-blockers) as time-varying covariates.
Fractional pulse pressure (PPf), which is
calculated as pulse pressure divided by
mean arterial pressure, has recently been
proposed as a new parameter of the pul-
satile component of blood pressure (16).
PPf is thought to more directly reﬂect arte-
rial stiffness than pulse pressure, because
dividing by mean arterial pressure theoret-
ically cancels out the inﬂuence of cardiac
output and peripheral vascular resistance.
We also evaluated the predictive value of
thisvariablefornew-onsetdiabetesbymul-
tiple Cox regression analysis. Because each
blood pressure index is affected by aging
(10), we also conducted subgroup analyses
stratiﬁedbyage(cutoffpoint:age65years),
using the median age at baseline of all
included patients. The test for interaction
in the multiple Cox model was evaluated
with the interaction term. In addition, to
clarify the signiﬁcance of pulse pressure for
new-onsetdiabetes,theassociationsofboth
SBP and DBP with the incidence of new-
onset diabetes were examined by multiple
Cox regression analysis with SBP grouped
into two categories (SBP 160 mmHg and
160 mmHg SBP) and DBP plotted as a
continuous variable. This model was plot-
tedwiththemiddle80%ofthedistribution
of DBP for each SBP group, and the HR of a
DBP of 90 mmHg in the SBP 160 mmHg
category was assigned a reference value of
1.0. All statistical tests were two-sided with
anlevelof0.05andwereperformedusing
SAS (version 9.1; SAS Institute, Cary, NC).
RESULTS
Baseline characteristics
During 3.3  0.8 years of follow-up, 97
patients (3.6%) developed new-onset di-
abetes. Baseline characteristics of patients
with and without new-onset diabetes are
shown in Table 1. Patients developing di-
abetes were more likely to be male and
obese, less likely to have been randomly
assigned to a candesartan-based regimen,
and more likely to have had lower DBP,
higher pulse pressure, and LVH at base-
line. At the time of randomization, 1,702
(65.8%) patients without and 65 (67.0%)
patients with new-onset diabetes were
under treatment with antihypertensive
drugs (CCB 40.1 vs. 34.0%, P  0.229;
ACEinhibitor13.3vs.16.5%,P0.363;
ARB 17.9 vs. 22.7%, P  0.229; diuretic
3.1 vs. 5.2%, P  0.255; -blocker 12.9
vs. 16.5%, P  0.297; and -blocker 5.6
vs. 4.1%, P  0.542, respectively).
Predictors of new-onset diabetes
Multiple Cox regression analysis revealed
that pulse pressure (per 1 SD increase)
was an independent predictor of new-
onset diabetes (HR 1.44 [95% CI 1.15–
1.79], P  0.001) (Table 2). In addition,
risk was also signiﬁcantly associated with
malesex,BMI,LVH,andconcomitantuse
of diuretics. As reported previously, can-
desartan-based regimens signiﬁcantly re-
duced the risk of new-onset diabetes
compared with amlodipine-based regi-
mens (15).
Because pulse pressure was calcu-
lated as the difference between SBP and
DBP, we conducted separate analyses for
SBP and DBP and found that DBP (per 1
SD decrease) was also an independent
predictorfornew-onsetdiabetes,whereas
SBP (per 1 SD increase) was not (HR for
SBP 1.13 [95% CI 0.90–1.41], P 
0.284;andHRforDBP1.45[1.16–1.81],
P  0.001). Subgroup analysis stratiﬁed
by age (cutoff point: age 65 years) re-
vealed that pulse pressure remained sig-
niﬁcantly associated with the risk of new-
onset diabetes in both age-groups (aged
65years:HR1.72[95%CI1.18–2.49],
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1.77], P  0.042; and Pinteraction 
0.152). However, DBP was signiﬁcantly
associated with risk only in the group
aged 65 years, whereas whole SBP was
not associated in either age-group (for
SBP, aged 65 years: 1.20 [0.86–1.67],
P  0.284; aged 65 years: 1.16 [0.84–
1.59],P0.374;andPinteraction0.780;
for DBP, aged 65 years: 1.58 [1.10–
2.28], P  0.014; aged 65 years: 1.32
[0.99–1.76],P0.057;andPinteraction
0.290).
Because different combinations of
SBPandDBPgivethesamepulsepressure
value(e.g.,bloodpressuresof130/60and
180/110 mmHg both give a pulse pres-
sure of 70 mmHg), we evaluated the as-
sociationofcombinationsofSBPandDBP
with the risk of new-onset diabetes. As
shown in Fig. 1, a strong association with
risk was seen for higher pulse pressures
arising mainly due to a lower DBP. From
this result, we hypothesized that patients
at high risk of new-onset diabetes had in-
creased arterial stiffness. Accordingly, we
next examined the association between
PPfandtheriskofnew-onsetdiabetesand
found that PPf (per 1 SD increase) was an
independent predictor of new-onset dia-
betes (HR 1.49 [95% CI 1.21–1.84], P 
0.001). In subgroup analysis stratiﬁed by
age, PPf (per 1 SD increase) was signiﬁ-
cantly associated with the risk of new-
onset diabetes in both age-groups (aged
65: 1.88 [1.29–2.73], P  0.001; aged
65: 1.34 [1.03–1.74], P  0.027; and
Pinteraction  0.057). Because fewer pa-
tients developed diabetes with candesar-
tan- than amlodipine-based regimens, we
examined the difference in this effect
stratiﬁed by quartile of PPf. As shown in
Fig.2,atrendtoanincreasedincidenceof
new-onset diabetes with increasing PPf
was seen in patients with amlodipine-
based regimens, but not in those with
candesartan-based regimens (P  0.0234
for interaction in the quadratic term).
Candesartan-basedregimenssigniﬁcantly
suppressedtheincidenceofnew-onsetdi-
abetes in the highest quartile of PPf. This
result was not changed after adjustment
for baseline characteristics (data not
shown).
CONCLUSIONS — In this study, we
demonstrated that pulse pressure was a
predictor of new-onset diabetes in high-
risk hypertensive patients, independent
of the effects of antihypertensive treat-
ment and other possible risk factors for
new-onset diabetes. Further, a higher
pulse pressure arising mainly due to a
lower DBP, indicating that the increased
pulse pressure resulted largely from in-
creased arterial stiffness, was associated
with a higher risk of new-onset diabetes.
This ﬁnding suggests that increased arte-
rial stiffness, reﬂected in an increased
pulse pressure, may be related to the pro-
cess of new-onset diabetes in high-risk
hypertensive patients, albeit that the
mechanism of this association remains to
be elucidated.
Twopotentialinterpretationsmayex-
plain these results. First, increased pulse
pressure may be a surrogate marker for
the risk of new-onset diabetes. Support-
Table 1—Baseline characteristics
Total NOD () NOD (	)
n 2,685 2,588 97
Candesartan* 1,343 (50.0) 1,305 (50.4) 38 (39.2)
Prior antihypertensive treatment 1,767 (65.8) 1,702 (65.8) 65 (67.0)
Age (years) 63.7  11.1 63.7  11.2 64.9  10.0
Male sex* 1,471 (54.8) 1,406 (54.3) 65 (67.0)
BMI (kg/m
2)* 24.8  3.6 24.1  3.5 25.2  3.4
SBP (mmHg) 165.0  14.8 165.0  14.8 165.7  16.1
DBP (mmHg)* 94.3  11.3 94.4  11.3 90.5  11.7
Pulse pressure (mmHg)* 70.8  15.8 70.6  15.7 75.2  18.4
Heart rate (beats/min) 71.4  10.9 71.4  10.9 71.2  9.5
Hyperlipidemia 1,178 (43.9) 1,136 (43.9) 42 (43.3)
Smoking
Never 1,825 (68.0) 1,766 (68.2) 59 (60.8)
Ever 273 (10.2) 261 (10.1) 12 (12.4)
Current 587 (21.9) 561 (21.7) 26 (26.8)
Cerebrovascular disease† 344 (12.8) 330 (12.8) 14 (14.4)
LVH* 1,139 (42.4) 1,088 (42.0) 51 (52.6)
Ischemic heart disease 393 (14.6) 381 (14.7) 12 (12.3)
Proteinuria 548 (20.4) 530 (20.5) 18 (18.6)
Renal dysfunction 205 (7.6) 196 (7.6) 9 (9.3)
Peripheral vascular disease 37 (1.4) 35 (1.4) 2 (2.1)
Data are n (%) or means  SD. *P  0.05, NOD () vs. NOD (	). †Stroke and transient ischemic attack.
NOD, new-onset diabetes.
Table 2—Predictors of new-onset diabetes by multiple Cox regression analysis
Variables, unit of increase HR (95% CI) P value
Pulse pressure, per 1 SD increase 1.44 (1.151.79) 0.001
Prior antihypertensive treatment, yes 0.97 (0.611.54) 0.901
Allocated drug, candesartan 0.64 (0.420.97) 0.037
Sex, male 1.77 (1.072.92) 0.026
Age, per 10 years 1.09 (0.871.36) 0.460
BMI, per 1 kg/m
2 increase 1.11 (1.061.17) 0.001
Heart rate, per 1 SD increase 1.01 (0.821.23) 0.960
Hyperlipidemia, yes 1.04 (0.681.57) 0.867
Smoking
Ever 1.03 (0.522.04) 0.942
Current 1.22 (0.722.06) 0.458
Cerebrovascular disease, yes 1.48 (0.802.75) 0.214
LVH, yes 1.75 (1.132.72) 0.013
Ischemic heart disease, yes 0.91 (0.471.76) 0.777
Renal damage, yes* 1.10 (0.681.79) 0.694
Peripheral vascular disease, yes 1.49 (0.366.16) 0.581
Additional use of diuretics, yes 2.10 (1.253.52) 0.005
Additional use of -blockers, yes 0.70 (0.401.24) 0.226
Additional use of -blockers, yes 0.63 (0.321.24) 0.185
DataareHR(95%CI)andareadjustedforeachvariable.*Renaldamage,proteinuria,andrenaldysfunction.
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sure,reﬂectingincreasedarterialstiffness,
was observed in hypertensive patients
with metabolic syndrome than in those
without (17). Further, accumulating evi-
dence supports the concept of increased
arterial stiffness in patients with a meta-
bolic disturbance, which is considered a
potential mechanism linking metabolic
disturbance to increased CVD risk (11–
13). Arterial properties are affected both
functionallyandstructurallybymanyfac-
tors, including aging, blood pressure,
sympatheticnervoussystemfunction,en-
dothelial function, inﬂammation, bioac-
tive peptides, and other cardiovascular
risk factors. Impaired glucose metabo-
lism, including metabolic syndrome and
insulin resistance, usually precedes the
development of overt type 2 diabetes
(18). Prolonged exposure to hyperglyce-
mic conditions can lead to increased arte-
rial stiffness via collagen cross-linking
due to nonenzymatic glycation, endothe-
lial dysfunction, inﬂammation, and local
activation of the renin-angiotensin-
aldosterone system in pre-diabetic as well
as diabetic individuals (18). Indeed, PPf,
representedasaparameterofthepulsatile
component of blood pressure, was supe-
rior to pulse pressure in terms of the risk
stratiﬁcation of new-onset diabetes.
Second,increasedpulsepressuremay
directlyaffectglucosemetabolism.Recent
ﬁndings have clariﬁed that microvascular
dysfunction may be a cause rather than a
consequence of hypertension (19). Mi-
crovasculardysfunctionmayalsocontrib-
utetoimpairedinsulin-mediatedchanges
in muscle perfusion and glucose metabo-
lism, providing a novel pathophysiologi-
cal framework for understanding the
association among hypertension, obesity,
and impaired insulin-mediated glucose
disposal (19,20). Microvascular dysfunc-
tion is thus a potential mechanism ex-
plaining the clustering of hypertension
and type 2 diabetes. Interestingly, rela-
tions between microvascular function
andbothaorticstiffnessandpressurepul-
satility have been reported (21). Abnor-
malities in peripheral vascular resistance
may have deleterious consequences for
aortic stiffness, and microvascular dys-
function may in turn be further aggra-
vated by increased transmission of the
forward wave into the microcirculation.
Accordingly,increasedpulsepressure,re-
ﬂectingincreasedarterialstiffness,maybe
both a cause and a consequence of micro-
vasculardysfunction,leadingtoa“vicious
cycle” in impaired glucose metabolism as
well as arteriosclerosis (9,19,20).
The present study also revealed that
electrocardiographic or echocardio-
graphic LVH at baseline was an indepen-
dent predictor of new-onset diabetes. In
their recent subanalysis of the Losartan
Intervention for Endpoint Reduction in
Hypertension(LIFE)study,Okietal.(22)
reported that in-treatment resolution or
continued absence of electrocardio-
graphic LVH was associated with a lower
incidenceofdiabetes.Becausepulsepres-
sure was positively related to LVH (23),
our study might validate their ﬁndings
from a different perspective. Interest-
ingly, in another subanalysis of the LIFE
study, Olsen et al. (24) found that treat-
ment with the ARB losartan was associ-
ated with less peripheral vascular
hypertrophy/rarefaction and higher insu-
lin sensitivity than that with atenolol,
supporting the hypothesis that microvas-
culardysfunctioninhypertensionmayin-
duce insulin resistance. In the present
study, the suppressive effect of the ARB
candesartan against new-onset diabetes
tended to strengthen as PPf increased.
These results suggest that ARBs decrease
the risk of new-onset diabetes partly via
the improvement of microcirculation.
Although the prevalence of diabetes
increaseswithage(25),itremainsunclear
whether age is a risk factor for new-onset
diabetes (6–8). In the present study, age
at baseline was not an independent pre-
dictor of new-onset diabetes. We as-
sumedthathigh-riskelderlyhypertensive
patients who did not have diabetes at
baseline were survivors who had avoided
thedevelopmentofdiabetesandthattheir
Figure 1—Risk of new-onset diabetes by SBP and DBP at enrollment. HR of DBP of 90 mmHg in
the SBP 160 mmHg category was assigned a reference value of 1.0.
Figure 2—Effect of candesartan and amlodipine on the incidence of new-onset diabetes stratiﬁed
by quartile of PPf.P P f (linear and quadratic terms), the allocated drugs, and their interaction
terms were entered in multiple Cox regression model. P value was calculated based on the Wald
test.
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ability to metabolize glucose may thus
have differed from those of younger sub-
jects. We also observed a strong associa-
tion between pulse pressure and new-
onsetdiabetesinpatientsaged65years,
possibly owing to the same mechanism.
Several limitations of this study war-
rant mention. First, it was conducted as a
post hoc analysis. Second, although we
found an interesting association between
pulse pressure and the risk of new-onset
diabetes, the CASE-J trial was not de-
signedtoprospectivelyevaluatethisasso-
ciation,andwewereconsequentlyunable
to elucidate causality, because we did not
directly measure parameters of arterial
stiffness or collect the data to clarify the
underlying mechanism. Third, we were
unable to include baseline data regarding
glucosemetabolismintothemultipleCox
regressionanalysisorinformationabouta
family history of diabetes, physical activ-
ity, or diet, which are well-known and
important risk factors for new-onset dia-
betes. Fourth, new-onset diabetes was
prespeciﬁed as the end point just before
the completion of the CASE-J trial. Ac-
cordingly, there was a possibility of non-
reporting bias, because the deﬁnition of
new-onsetdiabeteswasnotintheoriginal
protocol and determination of whether
new-onset diabetes had occurred de-
pended on the participating investigators’
reports. Thus, we may have underesti-
mated the overall incidence of new-onset
diabetes. Nevertheless, the present study
is the ﬁrst to examine the association of
pulsepressurewithnew-onsetdiabetesin
hypertensive patients and may provide
useful information in understanding the
underlying mechanism between hyper-
tension and new-onset diabetes. Finally,
becausethestudypopulationconsistedof
Japanese patients with high-risk hyper-
tension, the generalizability of our ﬁnd-
ings to other ethnic groups or general
populations may be limited.
In summary, we found that pulse
pressure is an independent predictor of
new-onset diabetes in high-risk Japa-
nese hypertensive patients. The devel-
opment of type 2 diabetes may involve
increased arterial stiffness, suggesting
the importance of the “microvascular
dysfunction” theory in the underlying
pathophysiological mechanism be-
tween hypertension and new-onset dia-
betes. To our knowledge, this study is
the ﬁrst to report the relation between
pulse pressure and new-onset diabetes
in hypertensive patients. Further stud-
ies are required to elucidate the signiﬁ-
cance of pulse pressure in new-onset
diabetes in hypertensive patients.
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